GB587992A
(en)
|
1944-12-11 |
1947-05-12 |
Charles William Scaife |
Improvements in and relating to the production of organic nitrogen compounds
|
US3578687A
(en)
|
1968-01-30 |
1971-05-11 |
Texaco Inc |
Process for producing 4-nitroalkanoic acids
|
US3819561A
(en)
|
1970-10-23 |
1974-06-25 |
Aerojet General Co |
Wetting agents for non-aqueous dispersions
|
JPS5313608B2
(pt)
|
1972-06-16 |
1978-05-11 |
|
|
JPS5318013B2
(pt)
|
1973-03-19 |
1978-06-13 |
|
|
US4599430A
(en)
|
1981-12-21 |
1986-07-08 |
The Standard Oil Company |
Nitrogenation of hydrocarbons, including the production of maleimide
|
JPS62132804A
(ja)
|
1985-12-05 |
1987-06-16 |
Aguro Kanesho Kk |
植物生長調節剤
|
US5412137A
(en)
|
1993-06-07 |
1995-05-02 |
Sandoz Ltd. |
Process for preparing phosphinyloxy propanaminium inner salt derivatives
|
BR9508554A
(pt)
|
1994-08-08 |
1997-11-25 |
Debiopharm Sa |
Preparação farmaceuticamente estável de oxaliplatina
|
EP0869941B1
(en)
|
1994-10-13 |
2001-12-12 |
Peptech Limited |
Modified polyunsaturated fatty acids
|
US5919816A
(en)
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
US5741211A
(en)
|
1995-10-26 |
1998-04-21 |
Medtronic, Inc. |
System and method for continuous monitoring of diabetes-related blood constituents
|
GB9618420D0
(en)
|
1996-09-04 |
1996-10-16 |
Scotia Holdings Plc |
Fatty acid treatment
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
KR100569319B1
(ko)
|
1997-10-30 |
2006-04-07 |
모리시타 진탄 가부시키가이샤 |
불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
|
EP1049695B1
(de)
|
1997-11-12 |
2002-02-13 |
Bayer Ag |
2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
|
US7795246B2
(en)
|
1998-08-06 |
2010-09-14 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
AU5565599A
(en)
|
1998-08-14 |
2000-03-06 |
Dante J. Marciani |
Chemically modified saponins and the use thereof as adjuvants
|
JP2002535330A
(ja)
|
1999-01-20 |
2002-10-22 |
アルツナイミッテルヴェルク ドレスデン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
薬剤としてのイミダゾ〔1,5−a〕−ピリド〔3、2−e〕−ピラジノンの使用
|
ATE384035T1
(de)
|
1999-04-01 |
2008-02-15 |
Esperion Therapeutics Inc |
Ether-verbindungen, zusammensetzungen und ihre verwendung
|
AU5319499A
(en)
|
1999-07-22 |
2001-02-13 |
Ivan L. Cameron |
Fatty acids to minimize cancer therapy side effects
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
AUPQ291499A0
(en)
|
1999-09-17 |
1999-10-07 |
Women's And Children's Hospital Adelaide |
Novel nitro and sulphur containing compounds
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
IL139455A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
US20010037598A1
(en)
|
1999-12-14 |
2001-11-08 |
Suppes Galen J. |
Process for producing cetane improvers from triglycerides
|
IL151299A0
(en)
|
2000-02-16 |
2003-04-10 |
Brigham & Womens Hospital |
Aspirin-triggered lipid mediators
|
AR034120A1
(es)
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
AR032318A1
(es)
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
AR030416A1
(es)
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
ES2239155T3
(es)
|
2000-06-28 |
2005-09-16 |
Zambon Group S.P.A. |
Proceso para la preparacion de nitroalquenos.
|
AR031129A1
(es)
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
DK1368022T3
(da)
|
2001-03-02 |
2007-10-01 |
Debiopharm Sa |
Anvendelse af en flaske indeholdende en oxaliplatinoplösning
|
IL158322A0
(en)
|
2001-04-18 |
2004-05-12 |
Prometic Biosciences Inc |
Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
EP1407767A4
(en)
|
2001-06-18 |
2007-01-24 |
Yamada Sachiko |
AGONIST MEDICINAL PREPARATIONS PPAR $ G (G)
|
CN1571672A
(zh)
|
2001-08-17 |
2005-01-26 |
匹兹堡大学 |
给予雌二醇代谢物治疗或预防肥胖症、代谢综合征、糖尿病以及血管和肾脏疾病
|
GB0123961D0
(en)
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
IL161155A0
(en)
|
2001-11-02 |
2004-08-31 |
Pfizer Prod Inc |
Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
|
HN2002000317A
(es)
|
2001-11-02 |
2003-05-21 |
Pfizer |
Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
|
US20030166716A1
(en)
|
2001-11-06 |
2003-09-04 |
Serhan Charles N. |
Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
|
GB2388111A
(en)
|
2002-05-01 |
2003-11-05 |
Bayer Ag |
Novel imidazotriazinone compounds
|
US6684626B1
(en)
|
2002-07-30 |
2004-02-03 |
General Electric Company |
Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
MXPA05002883A
(es)
|
2002-08-20 |
2005-10-05 |
Protemix Corp Ltd |
Formas de dosis y terapias relacionadas.
|
AU2003272738B2
(en)
|
2002-09-27 |
2010-04-01 |
Martek Biosciences Corporation |
Docosahexaenoic acid for improved glycemic control
|
WO2004037311A2
(en)
|
2002-10-21 |
2004-05-06 |
Kensey Nash Corporation |
Device and methods for sequential, regional delivery of multiple cytotoxic agents
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
WO2005016864A1
(en)
|
2003-07-29 |
2005-02-24 |
The Arizona Disease Control Research Commission |
Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
|
US20050136103A1
(en)
|
2003-09-17 |
2005-06-23 |
Ben-Sasson Shmuel A. |
Compositions capable of facilitating penetration across a biological barrier
|
US7935365B2
(en)
|
2003-10-22 |
2011-05-03 |
Enzymotec, Ltd. |
Glycerophospholipids for the improvement of cognitive functions
|
CA2543522A1
(en)
|
2003-10-31 |
2005-05-12 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
CN1934072A
(zh)
|
2004-01-30 |
2007-03-21 |
派普林生物脂股份有限公司 |
治疗和载体分子
|
MXPA06011871A
(es)
|
2004-04-15 |
2007-10-08 |
Chiasma Inc |
Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
|
WO2005110396A2
(en)
|
2004-04-28 |
2005-11-24 |
Uab Research Foundation |
Nitrated lipids and methods of making and using thereof
|
BRPI0513508B1
(pt)
|
2004-07-19 |
2021-06-01 |
Biocon Limited |
Conjugados de insulina-oligômero, formulações e usos desses
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
JPWO2006011397A1
(ja)
|
2004-07-27 |
2008-05-01 |
興和株式会社 |
糖尿病の予防または治療のための薬剤
|
BRPI0516803A
(pt)
|
2004-11-19 |
2008-09-23 |
Martek Biosciences Corp |
oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
|
EP1817009A2
(en)
|
2004-11-24 |
2007-08-15 |
Spi Pharma, Inc. |
Orally disintegrating compositions
|
AU2011202664B2
(en)
|
2004-12-08 |
2012-04-05 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of Crohn's disease
|
WO2006086727A2
(en)
|
2005-02-09 |
2006-08-17 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
CA2620223A1
(en)
|
2005-09-02 |
2007-03-08 |
Abbott Laboratories |
Novel imidazo based heterocycles
|
GB0522569D0
(en)
|
2005-11-04 |
2005-12-14 |
Univ Bath |
Biocompatible drug delivery device
|
TW200815436A
(en)
|
2006-05-30 |
2008-04-01 |
Elbion Ag |
4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
WO2008008767A2
(en)
|
2006-07-14 |
2008-01-17 |
Cedars-Sinai Medical Center |
Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
|
US20100035989A1
(en)
|
2006-07-19 |
2010-02-11 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for the treatment of mucositis
|
CA2662594A1
(en)
|
2006-09-08 |
2008-03-13 |
Tokuyama Corporation |
Method and apparatus for producing a group iii nitride
|
ES2536906T3
(es)
|
2006-12-13 |
2015-05-29 |
Aska Pharmaceutical Co., Ltd. |
Derivado de quinoxalina
|
JPWO2008072778A1
(ja)
*
|
2006-12-13 |
2010-04-02 |
あすか製薬株式会社 |
尿路系疾患の処置剤
|
WO2008103753A2
(en)
|
2007-02-20 |
2008-08-28 |
Martek Biosciences Corporation |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
EP2152712B1
(en)
|
2007-05-11 |
2012-01-11 |
Pfizer Inc. |
Amino-heterocyclic compounds
|
DE102007032349A1
(de)
|
2007-07-11 |
2009-01-15 |
Bayer Healthcare Ag |
Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
|
DK2180787T3
(da)
|
2007-08-01 |
2014-02-03 |
Univ Pittsburgh |
Nitrooliesyremodulering af type ii-diabetes
|
AU2008301895A1
(en)
|
2007-09-14 |
2009-03-26 |
Resolvyx Pharmaceuticals, Inc. |
Oxylipin compounds for treating autoimmune diseases
|
CN103285394B
(zh)
|
2008-04-18 |
2016-01-20 |
犹他大学研究基金会 |
使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
|
CN102083787A
(zh)
|
2008-05-01 |
2011-06-01 |
康普雷克萨公司 |
乙烯基取代的脂肪酸
|
WO2009149496A1
(en)
|
2008-06-10 |
2009-12-17 |
Central Northern Adelaide Health Service |
Treatment of diabetes and complications thereof and related disorders
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
EP2299997A4
(en)
|
2008-06-19 |
2012-01-11 |
Univ Utah Res Found |
USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
|
JP5579715B2
(ja)
|
2008-07-29 |
2014-08-27 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
|
CA2984026C
(en)
|
2008-10-09 |
2020-02-11 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
EP2384114A4
(en)
|
2008-12-31 |
2013-10-23 |
Nitromega Corp |
NUTRACEUTICALS CONTAINING NITROPTANT ACIDS
|
US8937194B2
(en)
|
2008-12-31 |
2015-01-20 |
Nitromega Corp. |
Topical compositions containing nitro fatty acids
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基-雜環化合物
|
US20100286272A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
|
US20100286257A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
|
US20100286271A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Nitro-alkyl Compound Compositions
|
US20110082147A1
(en)
|
2009-07-24 |
2011-04-07 |
Concert Pharmaceuticals, Inc. |
Substituted imidazotriazines
|
RU2012106896A
(ru)
|
2009-07-29 |
2013-09-10 |
Феноменом Дискавериз Инк. |
Гидроксилированные жирные кислоты и их применение для лечения и диагностики заболеваний
|
WO2011014261A1
(en)
|
2009-07-31 |
2011-02-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Fatty acids as anti-inflammatory agents
|
WO2011028820A1
(en)
|
2009-09-02 |
2011-03-10 |
Concert Pharmaceuticals, Inc. |
Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
|
WO2011030351A2
(en)
|
2009-09-03 |
2011-03-17 |
Rubicon Research Private Limited |
Taste - masked pharmaceutical compositions
|
CA2781276A1
(en)
|
2009-10-02 |
2011-04-07 |
Complexa, Inc. |
Heteroatom containing substituted fatty acids
|
CN102822152A
(zh)
|
2009-11-09 |
2012-12-12 |
诺瓦德克斯制药股份有限公司 |
新颖的1,3-噁唑烷化合物及其作为肾素抑制剂的用途
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
RU2567049C2
(ru)
|
2010-03-15 |
2015-10-27 |
Ульрих ДИТЦ |
Применение нитрокарбоновых кислот для лечения, диагностики и профилактики агрессивных форм заживления
|
BR112012027915A2
(pt)
|
2010-05-13 |
2018-10-23 |
Nitromega Corp |
nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
|
US20110319325A1
(en)
|
2010-06-28 |
2011-12-29 |
Complexa, Inc. |
Multi-component pharmaceuticals for treating diabetes
|
EP2619208B1
(en)
|
2010-09-20 |
2016-11-09 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
EP2769980B1
(en)
|
2011-10-07 |
2016-02-03 |
Eisai R&D Management Co., Ltd. |
Pyrazoloquinoline derivative as pde9 inhibitors
|
MX370433B
(es)
|
2011-10-10 |
2019-12-13 |
H Lundbeck As |
Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
DE102012008730A1
(de)
|
2011-12-02 |
2013-06-06 |
Dr. Budz GmbH |
Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
|
AP2014007820A0
(en)
|
2012-01-26 |
2014-07-31 |
Lundbeck & Co As H |
PDE9 inhibitors with imidazo triazinone backbone
|
AU2013214846B2
(en)
|
2012-02-01 |
2017-09-07 |
City Of Hope |
Ribonucleotide reductase inhibitors and methods of use
|
US10435367B2
(en)
|
2013-03-14 |
2019-10-08 |
City Of Hope |
Indirubin derivatives, and uses thereof
|
US20150018417A1
(en)
|
2012-02-03 |
2015-01-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Fatty acids as anti-inflammatory agents
|
EP2828262A4
(en)
|
2012-03-19 |
2015-09-23 |
Forum Pharmaceuticals Inc |
IMIDAZOTRIAZINONVERBINDUNGEN
|
US10058688B2
(en)
|
2012-05-09 |
2018-08-28 |
Massachusetts Institute Of Technology |
Medicament, method, and drug delivery device for treatment of ovarian cancer
|
DK2890384T3
(da)
|
2012-08-31 |
2022-01-10 |
Taris Biomedical Llc |
Lægemiddelleveringsystemer og fremgangsmåder til behandling af blærekræft omfattende oxaliplatin
|
US20140271844A1
(en)
|
2013-03-15 |
2014-09-18 |
Nitromega Corp. |
Compositions containing nitro fatty acids
|
US9301926B2
(en)
|
2013-04-10 |
2016-04-05 |
Massachusetts Institute Of Technology |
Local drug delivery devices and methods for treating cancer
|
WO2014183108A1
(en)
|
2013-05-10 |
2014-11-13 |
Nitromega Corp. |
Nutritional or dietary supplements containing fatty acids and nitrite
|
WO2014204872A2
(en)
|
2013-06-14 |
2014-12-24 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
WO2015023557A1
(en)
|
2013-08-12 |
2015-02-19 |
Nanomedical Systems, Inc. |
Device and method for sustained release of low water solubility therapeutic agent in solubilizer
|
WO2015073527A1
(en)
|
2013-11-12 |
2015-05-21 |
Complexa, Inc. |
Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
|
WO2015185499A1
(en)
|
2014-06-06 |
2015-12-10 |
H. Lundbeck A/S |
Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
|
JP2017527604A
(ja)
|
2014-09-17 |
2017-09-21 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC刺激剤
|
US20180092948A1
(en)
|
2015-04-02 |
2018-04-05 |
Aobiome Llc |
Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
|
DK3303339T3
(da)
|
2015-07-07 |
2021-04-12 |
H Lundbeck As |
Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
|
CN113440506A
(zh)
|
2015-10-02 |
2021-09-28 |
康普莱克夏公司 |
使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
|
AU2017220738B2
(en)
|
2016-02-19 |
2022-02-24 |
Phoenix Molecular Designs |
Carboxamide derivatives useful as RSK inhibitors
|
AU2017292650A1
(en)
|
2016-07-06 |
2018-12-13 |
H. Lundbeck A/S |
PDE9 inhibitors for treatment of peripheral diseases
|
WO2018218104A1
(en)
|
2017-05-26 |
2018-11-29 |
Imara, Inc. |
Methods of making and using pde9 inhibitors
|
JP2021526134A
(ja)
|
2018-05-25 |
2021-09-30 |
イマラ インク. |
6−[(3S,4S)−4−メチル−l−(ピリミジン−2−イルメチル)ピロリジン−3−イル]−3−テトラヒドロピラン−4−イル−7H−イミダゾ[l,5−A]ピラジン−8−オンの一水和物および結晶形態
|
KR20210053948A
(ko)
|
2018-08-31 |
2021-05-12 |
이마라 인크. |
겸상 세포 질환의 치료를 위한 pde9 억제제
|
CA3136128A1
(en)
|
2019-04-05 |
2020-10-08 |
Imara Inc. |
Pde9 inhibitors for treating sickle cell disease
|
WO2020227399A1
(en)
|
2019-05-07 |
2020-11-12 |
Imara Inc. |
Pde9 inhibitors for treating thalassemia
|
WO2022036111A1
(en)
|
2020-08-13 |
2022-02-17 |
Imara Inc. |
Methods and compositions for treating sickle cell disease
|
WO2022093852A1
(en)
|
2020-10-27 |
2022-05-05 |
Imara Inc. |
Pde9 inhibitors for treating cardiac failure
|